Featuring online engagement, assessment and scheduling, as well as in-person clinical testing and logistics, TourHealth is a scalable COVID-19 testing solution that promises rapid results.
The TourHealth partnership has been awarded a contract by the State of Florida to provide two semi-permanent testing sites in city of Miami and Miami Beach.
At each site, TourHealth will be able to process up to 625 tests per day for a total of 1,250 tests daily.
In Utah, the TourHealth partnership was selected as one of two vendors approved for a multi-vendor contract vehicle to provide scheduling, call center and test collection relating to COVID-19 testing for state agencies, local governments and educational institutions.
Under the TourHealth partnership, NIC will provide its Gov2Go technology solution, a mobile platform and personal government assistant, for citizen engagement, assessment and scheduling purposes.
Impact Health will supply credentialled clinical professionals to staff the testing units and provide testing results quickly and securely to individuals and government, integrating results with government contact tracing programs. Next Marketing will be responsible for onsite logistics, including supplying mobile testing units, site design, signage and operational support, as applicable.
NIC (NASDAQ: EGOV) is a leading digital government solutions and payments company, serving more than 7,000 federal, state and local government agencies across the nation.
Impact Health is in providing field-based health and wellness services and has led efforts to combat the COVID-19 pandemic through temperature scanning and testing with various FDA/EUA approved kits.
Impact Health supports both private and public sector clients including Yale New Haven Health, Ashley Furniture, CBS Broadcasting and the State of Kansas.
Next Marketing is in developing, executing and managing mobile tour solutions for corporate and government clients including the US Air Force, Air National Guard, General Motors, and Continental Tire.
Bioeq and Zydus partner for US commercialisation of Lucentis biosimilar NUFYMCO
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation